ESMO/LinkedIn
Dec 10, 2024, 17:32
Targeting claudins in pancreatic cancer shows promise – ESMO
ESMO – European Society for Medical Oncology posted the following on LinkedIn:
“IBI343, an anti-claudin 18.2 antibody-drug conjugate, shows promise in treating patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have positive CLDN18.2 expression and have failed or are intolerant to standard treatments. The updated data from the study presented at ESMOAsia24 indicates that IBI343 has a favorable safety profile and encouraging efficacy. Targeting claudins is a significant step forward in the pursuit of precision oncology.
To learn more about these results, read the ESMO Daily Reporter article.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 10, 2024, 17:32
Dec 10, 2024, 17:28
Dec 10, 2024, 17:04
Dec 10, 2024, 16:55
Dec 10, 2024, 16:40
Dec 10, 2024, 16:34
Dec 10, 2024, 16:32
Dec 10, 2024, 16:19
Dec 10, 2024, 16:07
Dec 10, 2024, 16:04